Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

Blood (2024) 144 (Supplement 1): 3461.

https://doi.org/10.1182/blood-2024-201998

Published: 2024

Journal Articles

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

Blood (2024) 144 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2024-202005

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Parmeshwar N Amatya, Jingyu Xiang, Julie O'Neal, Julie K. Ritchey, Alun J Carter, Matthew L. Cooper, John DiPersio

Blood (2023) 142 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2023-187449

Published: 2023

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 466.

https://doi.org/10.1182/blood-2023-184923

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella

Blood (2023) 142 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2023-178868

Published: 2023

Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio

Blood (2023) 142 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2023-186015

Published: 2023

Journal Articles

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Sena Kim, Sora Lim, Boram Kim, Julie Ritchey, Kiran Vij, Julie Prior, Lynne Marsala, Alyssa Stoner, Feng Gao, Samuel Achilefu, Matthew L. Cooper, John F. DiPersio, Jaebok Choi

Blood (2023) 141 (8): 945–950.

https://doi.org/10.1182/blood.2021012687

Published: 2023

Includes: Supplemental data

Journal Articles

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 7400–7401.

https://doi.org/10.1182/blood-2022-157199

Published: 2022

Journal Articles

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey

Blood (2022) 140 (Supplement 1): 12686–12687.

https://doi.org/10.1182/blood-2022-167715

Published: 2022

Journal Articles

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

Armin Ghobadi, Ibrahim Aldoss, Frederick L. Locke, Ryan J. Mattison, Deepa Bhojwani, Shannon L. Maude, Preeta Dasgupta, Karen Gheesling Mullis, Ayman Kabakibi, Alexander S. Hamil, Tom Leedom, Kenneth Chrobak, Eileen McNulty, Jan K Davidson-Moncada, Matthew L Cooper, John F. DiPersio

Blood (2021) 138 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2021-146841

Published: 2021

Journal Articles

Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies

Tom Leedom, Alexander S. Hamil, Somayeh Pouyanfard, Jennifer Govero, Rachel Langland, Anna Ballard, Liz Schwarzkopf, Andrew Martens, Andrew Espenschied, Pooja Vinay, Michael James, Nitin Mahajan, David H Spencer, Kenneth M Chrobak, Matthew L Cooper, Ayman Kabakibi

Blood (2021) 138 (Supplement 1): 2772.

https://doi.org/10.1182/blood-2021-153150

Published: 2021

Journal Articles

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Miriam Y Kim, Matthew L Cooper, Julie K Ritchey, Julia Hollaway, John F. DiPersio

Blood (2021) 138 (Supplement 1): 734.

https://doi.org/10.1182/blood-2021-150935

Published: 2021

Journal Articles

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood (2020) 136 (20): 2308–2318.

https://doi.org/10.1182/blood.2020006619

Published: 2020

Includes: Supplemental data

Journal Articles

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Parmeshwar N Amatya, PhD, Alun J Carter, PhD BSc, Julie K Ritchey, Jessica Niswonger, Matthew L Cooper, PhD, Jonathan A Pachter, PhD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139904

Published: 2020

Journal Articles

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

Parmeshwar Amatya, PhD, Matthew L. Cooper, PhD, Alun J Carter, PhD BSc, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2068.

https://doi.org/10.1182/blood-2019-126165

Published: 2019

Journal Articles

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Stephen P. Persaud, MD PhD, Matthew L. Cooper, PhD, Julie K. Ritchey, Michael P. Rettig, PhD, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 3200.

https://doi.org/10.1182/blood-2019-123519

Published: 2019

Journal Articles

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Melissa M Berrien-Elliott, PhD, Wong Pamela, B.S., Carly Neal, B.S., Julia A Wagner, PhD, Michelle Becker-Hapak, BS, Tim Schappe, BS, Matthew L. Cooper, PhD, Emily M Mace, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3237.

https://doi.org/10.1182/blood-2019-129162

Published: 2019

Journal Articles

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Karl W. Staser, MD PhD, Matthew L. Cooper, PhD, Jaebok Choi, PhD, Anand Chukka, Kidist Ashami, BA, Jessica Niswonger, Jaehan Park, Byung Ha Lee, PhD, Shunqiang Li, PhD, Amanda F Cashen, MD, Amy Musiek, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 340.

https://doi.org/10.1182/blood-2018-99-119375

Published: 2018

NARROW

WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) - Subgroup Analysis of WU-CART-007 1001

WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

The Dual PI3Kδγ Inhibitor Duvelisib Potently Inhibits IL-6 Production and Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function in Vitro and In Vivo

Identification of Small Molecule Kinase Inhibitors That Potently and Reversibly Block Chimeric Antigen Receptor T Cell Proliferation and Cytotoxicity

CD45-ADC Plus Janus Kinase (JAK) Inhibitors As Conditioning for MHC-Mismatched Murine Hematopoietic Stem Cell Transplantation Is Associated with Minimal Toxicity and Graft Versus Host Disease

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only